A rare inflammatory muscle disease is leaving patients undiagnosed for years, with consequences that go far beyond physical pain.
Climbing a flight of stairs. Carrying a bag of groceries. Wrapping your arms around someone you love. For most people, these are thoughtless movements. For someone living with myositis, they can be out of reach entirely.
Myositis is a chronic autoimmune disease in which the immune system turns against muscle fibers, causing inflammation that gradually erodes strength and mobility. Symptoms can arrive suddenly or build slowly over time, and the damage does not always stop at the muscles. The condition can affect the skin, joints, lungs, heart, and gastrointestinal tract, making it one of the more medically complex diagnoses a patient can receive.
A disease too rare to be on most doctors’ radar
Roughly 75,000 people in the United States are currently living with this disease. That number sounds significant until you compare it to something like diabetes, which affects approximately 40 million Americans and commands an entire infrastructure of trained specialists. Myositis, by contrast, exists in a kind of medical blind spot. Many primary care physicians go their entire careers without seeing a single case, and the pool of rheumatologists who specialize in it remains small.
That scarcity has real consequences. Patients frequently wait up to five years for an accurate diagnosis. During that window, the disease progresses. Opportunities for early intervention are lost. And patients are left cycling through appointments without answers.
The overlap between myositis symptoms and those of other conditions makes this worse. Misdiagnosis is not the exception. It is the norm.
The five forms of myositis
There are five primary types of myositis, each with its own profile and challenges.
Dermatomyositis is marked by muscle weakness and a distinctive skin rash. It is the only form that commonly affects children. Black individuals are three times more likely to be diagnosed with dermatomyositis than white individuals, a disparity that researchers are still working to understand.
Polymyositis typically begins in the mid-section of the body and develops in adults over 20. It worsens progressively over time and does not come with the visible skin symptoms of dermatomyositis.
Immune mediated necrotizing myositis is among the most severe forms. It can cause significant structural muscle damage in a relatively short period.
Inclusion body myositis moves slowly but is uniquely resistant to treatment. It primarily affects older adults and does not respond to immunotherapy, making it one of the harder forms to manage medically.
Anti-synthetase syndrome is tied to specific autoantibodies in the blood and tends to produce a wider range of complications than the other forms.
The diagnostic process and why it takes so long
Diagnosing this disease requires a combination of blood tests, imaging scans, and in many cases, biopsies of both muscle and skin tissue. There is no single test that confirms it. That complexity, combined with limited physician familiarity, is what drives the diagnostic delay.
Patients who suspect myositis are encouraged to track their symptoms in detail and bring documented records to medical appointments. The Myositis Association has long pushed for broader physician education, arguing that recognition is the first barrier to treatment.
Treatment options and their limits
There is no universal treatment protocol for this disease. Immunotherapy is the primary approach for most forms, aimed at calming the overactive immune response driving the inflammation. Physical therapy runs alongside it, focused on preserving and rebuilding muscle function.
Inclusion body myositis is the exception. It does not respond to immunotherapy, so physical therapy becomes the central and only management strategy. For patients with this form, treatment is largely about slowing decline rather than reversing it.
The mental health toll that goes unspoken
The physical impact of myositis is well documented. The psychological weight of it is less often discussed.
Losing control over basic movements creates real psychological consequences. Anxiety and depression are common among myositis patients, and the burden can be especially hard on children diagnosed with juvenile forms of the disease. Families managing a pediatric diagnosis are often advised to build mental health support into their care plan from the beginning, not as an afterthought.
For anyone experiencing symptoms consistent with myositis, a referral to a rheumatologist is the most direct path forward. Earlier intervention consistently leads to better outcomes and a stronger foundation for long-term management.
